Engage with experts and peers on all aspects of cardiac catheterization.
Richard A. Lange, MD, MBA and L. David Hillis, MD
A study of data from FRANCE 2, a prospectively maintained, multicenter registry of the French national experience with transcatheter aortic valve implantation (TAVI), has now been published in the New England Journal of Medicine. The registry captured every TAVI performed at all 34 active centers in France and Monaco; it therefore reflects “real-life” experience with TAVI in patients with…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: aortic stenosis, aortic valve replacement, CoreValve, FDA, FRANCE 2, PARTNER, Sapien, TAVI
- 0 Recommendations
- |
- 4 Comments
Gregg W Stone, MD
In a new meta-analysis Dr. Gregg Stone and members of the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation concluded that reduction in target-vessel revascularization (TVR) associated with drug-eluting stents (DES) in primary PCI provided a powerful reason for continued use of DES in primary PCI. An accompanying editorial by James Brophy focused on several potential DES weaknesses in the study….
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: bare metal stents, drug-eluting stents, Primary PCI, stents
- 0 Recommendations
- |
- 3 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
“We said it before, and we’ll say it again: an assessment of platelet reactivity by this method doesn’t effectively identify individuals at high risk for a cardiovascular event following PCI.”
Tags: clopidogrel, platelet reactivity, prasugrel
- 1 Recommendations
- |
- 1 Comment
Richard A. Lange, MD, MBA and L. David Hillis, MD
Biodegradable stents: here to stay… or will they disappear? A newly-released study reports the long-term results of the first-in-man fully biodegradable coronary stent.
Tags: biodegradable stents, PCI, stents
- 1 Recommendations
- |
- 0 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
In the CLOSURE I trial (Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack Due to a Presumed Paradoxical Embolism through a Patent Foramen Ovale), 909 patients with a PFO who had a stroke or a transient ischemic attack (TIA) of unclear etiology were randomly assigned to device…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: CLOSURE I, PFO Closure, stroke prevention
- 1 Recommendations
- |
- 5 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
According to a recently published study by Chan and colleagues, only 50% of the PCIs performed for nonacute indications were classified as appropriate, according to appropriate use criteria (AUC); 38% were “uncertain,” and 12% were inappropriate. In a new expedited publication, Marso and colleagues retort by expressing concerns with the “current” PCI AUC (see also our CardioExchange news coverage…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: appropriate use criteria, CABG, CathPCI registry, PCI
- 2 Recommendations
- |
- 4 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
The current standard of care for individuals undergoing carotid arterial stenting (CAS) entails the use of an embolic protection device (EPD) to minimize the risk for embolic stroke. At present, the only FDA-approved EPD is a filter that is placed distal to the stenosis (i.e., it is advanced across the lesion) before stenting. In a recently completed randomized trial, a proximal balloon occlusion device…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: carotid artery stenting, distal embolic filter, embolic protection device, PROFI, proximal balloon occlusion
- 0 Recommendations
- |
- 3 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Gravina Island Bridge (also known as The Bridge to Nowhere) was a proposed bridge to replace the ferry that currently connects Ketchikan, Alaska (population, 14,000) to the Ketchikan International Airport on Gravina Island (population, 50) at a projected cost of $398 million. The bridge was to have been nearly as long as the Golden Gate…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: BRIDGE trial, cangrelor, Cardiac surgery, thienopyridines, VerifyNOW
- 1 Recommendations
- |
- 2 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
In a 2009 NEJM article, the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) study group published 1 to 5 (mean, 2.7) year follow-up data for almost 48,000 registry patients who received a bare metal (BMS) or drug-eluting coronary stent (DES) between 2003 and 2006, concluding that the two are associated with a similar long-term incidence…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
- 1 Recommendations
- |
- 0 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
The controversy over the use of genetic testing to guide antiplatelet therapy reminds us of a WWF (Worldwide Wrestling Federation) tag team match. What we agree upon (the match rules): Clopidogrel is a prodrug activated by several enzymes, including CYP2C19, and common genetic variations alter CYP2C19 activity. Here’s where the wrestling match begins: Are the CYP2C19 genetic…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: ACC, AHA, clopidogrel, CYP2C19, FDA, genetic testing, stent thrombosis
- 2 Recommendations
- |
- 3 Comments
